To compare the effectiveness and safety of Vericiguat with Standard Medical Treatment in Patients with Heart Failure and Reduced Ejection Fraction
Age >18 years of any gender
Chronic heart failure (New York Heart Association [NYHA] functional class II, III, or IV), a reduced left ventricular ejection fraction of less than 45% within 12 months before randomization
Elevated natriuretic peptide level: (For patients in sinus rhythm, the criteria include a plasma B-type natriuretic peptide (BNP) level of at least 300 pg per milliliter or an NT-proBNP level of at least 1000 pg per milliliter. For patients in atrial fibrillation, the criteria included a BNP level of at least 500 pg per milliliter or an NT-proBNP level of at least 1600 pg per milliliter).
Evidence of worsening heart failure.
Systolic blood pressure of less than 100 mm Hg.
Concurrent or anticipated use of long-acting nitrates.
Use of intravenous inotropes or implantable left ventricular assist devices.
Not on standard of care medical treatment for heart failure.
National Institute of Cardiovascular Diseases, Pakistan
Lead sponsor
Horizon Pharmaceuticals
Collaborator